News

The U.S. Food and Drug Administration has granted rare pediatric disease designation to Regenxbio’s one-time gene therapy RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the most common forms of Batten disease. Regenxbio plans to submit an investigational new drug (IND) to the FDA…

G71.01 is, literally, the code for Duchenne muscular dystrophy.  Q93.51 stands for Angelman syndrome, and E75.4 covers neuronal ceroid lipofuscinosis (NCLs) and so includes Batten disease. All three designations are among some 70,000 diseases listed in the latest iteration of the International Classification of Disease (ICD). Known…

A mouse model representing CLN6 disease, a subtype of Batten disease, shows that females have different symptoms and a shorter lifespan than males, a study reports. This highlights the need for considering sex-specific differences in Batten disease progression when treating patients and developing therapeutic strategies. The study, “…

The U.S. Food and Drug Administration(FDA) is updating its 2015 draft guidelines for drug discovery in rare diseases, with new guidance on natural history— how disorders such as spinal muscle atrophy(SMA) run their course if untreated — the choice of “efficacy endpoints” in clinical trials, and how…

Mutated forms of CLN3 protein may be involved in the abnormal activation of signals in brain cells that, in excess, could promote cell death, a study has found, which suggests that inhibiting these signaling cascades could represent a new therapeutic strategy to prevent the progression of the juvenile form of…

A team of Italian researchers suggests that CLN3 disease, also known as juvenile Batten disease, should be included in the differential diagnosis of people with autophagic vacuolar myopathy (AVM), after describing the case of a man who received an accurate diagnosis only after undergoing a muscle biopsy.

The activation of a recycling pathway, a process called autophagy, which leads to large storage vesicles in muscle cells, is a feature of all forms of juvenile Batten disease, a small study suggests. The study, “Autophagic vacuolar myopathy is a common feature of CLN3 disease,” was published in the …

Amicus Therapeutics is recruiting children for its new Phase 1/2 clinical trial that will assess the safety and efficacy of an investigational gene therapy for Batten disease caused by CLN3 gene mutations. The first child has completed a one-month observation period following dosing, with no reports of serious…

Cash-strapped governments across the 28-member European Union are struggling to control runaway healthcare expenditures — at exactly the same time as the promise of new but expensive therapies to treat rare diseases has never been greater. That’s the paradox faced by pharmaceutical companies as well as patient advocacy groups in…

New mutations have been found in PPT1 and TPP1, the two genes associated with neuronal ceroid lipofuscinoses type 1 and type 2 (NCL1 and NCL2), respectively, in a population of patients in India, researchers reported. Their study, “Batten disease: biochemical and molecular characterization revealing novel…